166 related articles for article (PubMed ID: 38463231)
1. Prognostic value of inflammatory nutritional scores in locally advanced esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multicenter study in China.
Xu J; Hong Z; Cai Y; Chen Z; Lin J; Yuan X; Chen S; Xie J; Kang M; Ke S
Front Oncol; 2024; 14():1279733. PubMed ID: 38463231
[TBL] [Abstract][Full Text] [Related]
2. Preoperative maximal voluntary ventilation, hemoglobin, albumin, lymphocytes and platelets predict postoperative survival in esophageal squamous cell carcinoma.
Hu SJ; Zhao XK; Song X; Lei LL; Han WL; Xu RH; Wang R; Zhou FY; Wang L; Wang LD
World J Gastroenterol; 2021 Jan; 27(4):321-335. PubMed ID: 33584065
[TBL] [Abstract][Full Text] [Related]
3. The preoperative hemoglobin, albumin, lymphocyte and platelet (HALP) score is a useful predictor in patients with resectable esophageal squamous cell carcinoma.
Feng JF; Wang L; Yang X
Bosn J Basic Med Sci; 2021 Dec; 21(6):773-781. PubMed ID: 33974528
[TBL] [Abstract][Full Text] [Related]
4. Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.
Shi Y; Shen G; Zeng Y; Ju M; Chen X; He C; Liang L; Ge X; Sun X; Di X
Int Immunopharmacol; 2023 Oct; 123():110773. PubMed ID: 37562292
[TBL] [Abstract][Full Text] [Related]
5. The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Front Immunol; 2022; 13():1015365. PubMed ID: 36505443
[TBL] [Abstract][Full Text] [Related]
6. The preoperative hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for non-small cell lung cancer patients undergoing adjuvant chemotherapy: a retrospective study.
Wei S; Shao J; Wang J; Wang G
Ann Transl Med; 2022 Apr; 10(8):457. PubMed ID: 35571436
[TBL] [Abstract][Full Text] [Related]
7. Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores.
Feng J; Wang L; Yang X; Chen Q; Cheng X
J Inflamm Res; 2022; 15():3783-3796. PubMed ID: 35832830
[TBL] [Abstract][Full Text] [Related]
8. HALP score based on hemoglobin, albumin, lymphocyte and platelet can predict the prognosis of tongue squamous cell carcinoma patients.
Zhang D; Chen S; Cao W; Geng N; Feng C
Heliyon; 2023 Sep; 9(9):e20126. PubMed ID: 37809958
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy sensitizes locally advanced esophageal squamous cell carcinoma to PD-1 blockade for a higher pathological complete response rate and survival.
Wang P; Lei M; Weng G; Huang R; Lin H; Wei W; Chen Y; He H; Chen P; Zhang D; Chen W; Zhou H; Gao P; Liu S; Wang F
Transl Oncol; 2023 Oct; 36():101736. PubMed ID: 37478670
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study.
Huang Z; Li S; Yang X; Lu F; Huang M; Zhang S; Xiong Y; Zhang P; Si J; Ma Y; Yang Y
Cancer Manag Res; 2019; 11():1299-1308. PubMed ID: 30799956
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
Qi WX; Wang X; Li C; Li S; Li H; Xu F; Chen J; Zhao S; Li H
Thorac Cancer; 2023 Jun; 14(17):1556-1566. PubMed ID: 37089116
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy.
Qiu J; Yang J; Yu Y; Wang Z; Lin H; Ke D; Zheng H; Li J; Yao Q
BMC Cancer; 2023 Jun; 23(1):597. PubMed ID: 37380982
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma.
Zhao K; Wang C; Shi F; Li M; Yu J
Transl Cancer Res; 2020 Jun; 9(6):3842-3853. PubMed ID: 35117751
[TBL] [Abstract][Full Text] [Related]
14. Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma.
Wang H; Jiang Z; Wang Q; Wu T; Guo F; Xu Z; Yang W; Yang S; Feng S; Wang X; Chen S; Cheng C; Chen W
Eur J Cancer; 2023 Jun; 186():196-210. PubMed ID: 37045666
[TBL] [Abstract][Full Text] [Related]
15. The status of perineural invasion predicts the outcomes of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma.
Ning ZH; Zhao W; Li XD; Chen LJ; Xu B; Gu WD; Shao YJ; Xu Y; Huang J; Pei HL; Jiang JT
Int J Clin Exp Pathol; 2015; 8(6):6881-90. PubMed ID: 26261575
[TBL] [Abstract][Full Text] [Related]
16. The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma.
Cong L; Hu L
Int Immunopharmacol; 2017 May; 46():75-79. PubMed ID: 28268208
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer.
Han W; Weng K; Zhang P; Hong Z
Front Surg; 2022; 9():1091601. PubMed ID: 36684142
[TBL] [Abstract][Full Text] [Related]
18. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study.
Xia P; Li P; Wu S; Wang Y; Ye P; Zhang C; Hu J; Kidane B; Lampridis S; Velotta JB; Wakefield CJ; Zhu L; Wang L
Ann Transl Med; 2022 Sep; 10(18):991. PubMed ID: 36267734
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of tumor regression grade in esophageal squamous cell carcinoma after neoadjuvant chemoradiation.
Zhang C; Xu F; Qiang Y; Cong ZZ; Wang Q; Zhang Z; Luo C; Qiu BM; Hu LW; Shen Y
Front Surg; 2022; 9():1029575. PubMed ID: 36684331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
